Glucagon-like peptide-1 receptor agonists (GLP-1s) have shown tremendous promise at controlling diabetes, and causing weight loss, and increasingly are being shown to reduce the burden of cardiovascular disease and other chronic conditions. While there is significant clinical promise and indications continue to accumulate, the costs of these treatments present coverage challenges to insurers and employers, who are increasingly limiting access and providing barriers to patients. These barriers may interact with racial disparities present for many of these conditions. The panel will tackle the issue of health equity of GLP1s, presenting diverse perspectives from employers, clinicians, and pharmaceutical manufacturers.
Panelists:
Shantanu Nundy, MD, EVP Care Delivery and Chief Health Officer, Accolade
Gregory Daniel, PhD, MPH, Vice President & Head of Global Public Policy, Eli Lilly and Company
Katey Bey, Global Head, Total Rewards
Moderators:
Joseph Levy, PhD, Assistant Professor, Johns Hopkins Bloomberg School of Public Health
Conversations on the Business of Health
Webinar Series
This event is part of a larger series on 'Conversations on the Business of Health,' which will be one-hour webinars that will engage leaders in business and academia. We will explore questions such as:
Should companies invest in their employees’ health?
Are companies responsible for the health consequences of their products?
Will artificial intelligence actually advance health?
How can business offer healthcare in novel settings?
Moderated by faculty members and jointly hosted by the Bloomberg School of Public Health, the Carey Business School, the School of Nursing, and the School of Medicine, the series is open to all. Indeed, we invite you to spread the word as we seek participants both inside and outside of Johns Hopkins, including the business world.
The Hopkins Business of Health Initiative integrates the scholarship across Johns Hopkins University including the Carey Business School, Bloomberg School of Public Health, School of Nursing, and School of Medicine around a shared vision of a healthier America, supported by an affordable and equitable, high-value health system. In pursuit of this vision, our work focuses on the role of business and incentives through rigorous, objective, non-partisan, interdisciplinary research.
Информация по комментариям в разработке